申请人:Abbott Laboratories
公开号:US07241773B2
公开(公告)日:2007-07-10
Compounds of formula:
or pharmaceutically acceptable salts, esters, amides, or prodrugs thereof, wherein: A and G are each independently N or N+—O−; m and n are each independently 0, 1, or 2; X1 and X3 are each independently O, S, and —N(R1)—; X2 is O, S, —N(R1)—, —N(Ar2)—and —N(R2)C(O)—; Ar1 is a six-membered aromatic ring; Ar2 is cyclohexyl or a mono- or bicyclic aromatic ring, and R13 is hydrogen, alkyl, or halogen, as defined herein. The compounds are useful in treating conditions or disorders prevented by or ameliorated by nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formulas (I) and (II) and methods for using such compounds and compositions.
化合物的式子:或其药学上可接受的盐、酯、酰胺或前药,其中:A和G各自独立地为N或N+—O−;m和n各自独立地为0、1或2;X1和X3各自独立地为O、S和—N(R1)—;X2为O、S、—N(R1)—、—N(Ar2)—和—N(R2)C(O)—;Ar1为六元芳环;Ar2为环己基或单环或双环芳环,R13为氢、烷基或卤素,按照此处的定义。这些化合物在治疗由nAChR配体预防或缓解的疾病或疾病方面有用。还公开了具有式(I)和式(II)化合物的制药组合物及使用这种化合物和组合物的方法。